These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 25352807)

  • 1. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.
    Demin O; Yakovleva T; Kolobkov D; Demin O
    Front Pharmacol; 2014; 5():218. PubMed ID: 25352807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
    Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans.
    Lu Y; Griffen SC; Boulton DW; Leil TA
    Front Pharmacol; 2014; 5():274. PubMed ID: 25540623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.
    Ghezzi C; Yu AS; Hirayama BA; Kepe V; Liu J; Scafoglio C; Powell DR; Huang SC; Satyamurthy N; Barrio JR; Wright EM
    J Am Soc Nephrol; 2017 Mar; 28(3):802-810. PubMed ID: 27620988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin.
    Choi MK; Nam SJ; Ji HY; Park MJ; Choi JS; Song IS
    Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32183468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes.
    Peene B; Benhalima K
    Ther Adv Endocrinol Metab; 2014 Oct; 5(5):124-36. PubMed ID: 25419452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
    Sakaeda T; Kobuchi S; Yoshioka R; Haruna M; Takahata N; Ito Y; Sugano A; Fukuzawa K; Hayase T; Hayakawa T; Nakayama H; Takaoka Y; Tohkin M
    Int J Med Sci; 2018; 15(9):937-943. PubMed ID: 30008607
    [No Abstract]   [Full Text] [Related]  

  • 12. Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM.
    Osaki A; Shimoda Y; Okada J; Yamada E; Saito T; Nakajima Y; Ozawa A; Niijima Y; Okada S; Yamada M
    Diabetes Ther; 2019 Aug; 10(4):1531-1534. PubMed ID: 31197753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
    Mori K; Saito R; Nakamaru Y; Shimizu M; Yamazaki H
    Biopharm Drug Dispos; 2016 Nov; 37(8):491-506. PubMed ID: 27604638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks Associated with SGLT2 Inhibitors: An Overview.
    Singh M; Kumar A
    Curr Drug Saf; 2018; 13(2):84-91. PubMed ID: 29485006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.
    Madaan T; Akhtar M; Najmi AK
    Eur J Pharm Sci; 2016 Oct; 93():244-52. PubMed ID: 27531551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes.
    Moradi-Marjaneh R; Paseban M; Sahebkar A
    Phytother Res; 2019 Oct; 33(10):2518-2530. PubMed ID: 31359514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.
    Moses RG; Colagiuri S; Pollock C
    Australas Med J; 2014; 7(10):405-15. PubMed ID: 25379062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
    Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
    J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.
    Cai X; Yang W; Gao X; Chen Y; Zhou L; Zhang S; Han X; Ji L
    Obesity (Silver Spring); 2018 Jan; 26(1):70-80. PubMed ID: 29165885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.